Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents

Report from the Children's Oncology Group

Minnie Abromowitch, Richard Sposto, Sherrie Perkins, David Zwick, Stuart Siegel, Jonathan Finlay, Mitchell S. Cairo

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Pediatric lymphoblastic lymphoma (LL) has utilized treatment strategies similar to childhood acute lymphoblastic leukaemia (ALL) with prolonged maintenance chemotherapy. We report the results of a pilot study to estimate the feasibility, toxicity and efficacy of a 12-month aggressive multi-agent chemotherapy regimen in children and adolescents with advanced LL. Between July 1994 and June 1997, 85 eligible children and adolescents with advanced LL (Stage III/IV) were enrolled on this pilot study. Patients achieving a complete response following induction and consolidation received six cycles of maintenance chemotherapy for a total duration of 12 months. Grade III/IV toxicities included: hematological (80%), infections (20%), stomatitis and elevated transaminases, (29%). There were a total of 19 events, 13 relapses, two secondary acute myeloid leukaemia and four toxic deaths (5%). The 5-year event-free survival (EFS) and overall survival (OS) was 78 ± 4.5% and 85 ± 3.9%, respectively. Relapsed patients had a 5-year OS of only 33 ± 14%. Multivariate analysis failed to demonstrate age, gender, lactate dehydrogenase level, presence of marrow and/or central nervous system disease to have independent prognostic value. These results suggest that this experimental approach is safe and results in similar outcomes as more prolonged childhood ALL regimens.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalBritish Journal of Haematology
Volume143
Issue number2
DOIs
StatePublished - Oct 1 2008

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Therapy
Maintenance Chemotherapy
Therapeutics
Stomatitis
Survival
Poisons
Central Nervous System Diseases
Transaminases
L-Lactate Dehydrogenase
Acute Myeloid Leukemia
Disease-Free Survival
Multivariate Analysis
Bone Marrow
Pediatrics
Recurrence
Infection

Keywords

  • Adolescents
  • Children
  • Intensified multiagent chemotherapy
  • Lymphoblastic lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents : Report from the Children's Oncology Group. / Abromowitch, Minnie; Sposto, Richard; Perkins, Sherrie; Zwick, David; Siegel, Stuart; Finlay, Jonathan; Cairo, Mitchell S.

In: British Journal of Haematology, Vol. 143, No. 2, 01.10.2008, p. 261-267.

Research output: Contribution to journalArticle

@article{24cb63f619904d049ccedebfe03cc52f,
title = "Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: Report from the Children's Oncology Group",
abstract = "Pediatric lymphoblastic lymphoma (LL) has utilized treatment strategies similar to childhood acute lymphoblastic leukaemia (ALL) with prolonged maintenance chemotherapy. We report the results of a pilot study to estimate the feasibility, toxicity and efficacy of a 12-month aggressive multi-agent chemotherapy regimen in children and adolescents with advanced LL. Between July 1994 and June 1997, 85 eligible children and adolescents with advanced LL (Stage III/IV) were enrolled on this pilot study. Patients achieving a complete response following induction and consolidation received six cycles of maintenance chemotherapy for a total duration of 12 months. Grade III/IV toxicities included: hematological (80{\%}), infections (20{\%}), stomatitis and elevated transaminases, (29{\%}). There were a total of 19 events, 13 relapses, two secondary acute myeloid leukaemia and four toxic deaths (5{\%}). The 5-year event-free survival (EFS) and overall survival (OS) was 78 ± 4.5{\%} and 85 ± 3.9{\%}, respectively. Relapsed patients had a 5-year OS of only 33 ± 14{\%}. Multivariate analysis failed to demonstrate age, gender, lactate dehydrogenase level, presence of marrow and/or central nervous system disease to have independent prognostic value. These results suggest that this experimental approach is safe and results in similar outcomes as more prolonged childhood ALL regimens.",
keywords = "Adolescents, Children, Intensified multiagent chemotherapy, Lymphoblastic lymphoma",
author = "Minnie Abromowitch and Richard Sposto and Sherrie Perkins and David Zwick and Stuart Siegel and Jonathan Finlay and Cairo, {Mitchell S.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1111/j.1365-2141.2008.07320.x",
language = "English (US)",
volume = "143",
pages = "261--267",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents

T2 - Report from the Children's Oncology Group

AU - Abromowitch, Minnie

AU - Sposto, Richard

AU - Perkins, Sherrie

AU - Zwick, David

AU - Siegel, Stuart

AU - Finlay, Jonathan

AU - Cairo, Mitchell S.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Pediatric lymphoblastic lymphoma (LL) has utilized treatment strategies similar to childhood acute lymphoblastic leukaemia (ALL) with prolonged maintenance chemotherapy. We report the results of a pilot study to estimate the feasibility, toxicity and efficacy of a 12-month aggressive multi-agent chemotherapy regimen in children and adolescents with advanced LL. Between July 1994 and June 1997, 85 eligible children and adolescents with advanced LL (Stage III/IV) were enrolled on this pilot study. Patients achieving a complete response following induction and consolidation received six cycles of maintenance chemotherapy for a total duration of 12 months. Grade III/IV toxicities included: hematological (80%), infections (20%), stomatitis and elevated transaminases, (29%). There were a total of 19 events, 13 relapses, two secondary acute myeloid leukaemia and four toxic deaths (5%). The 5-year event-free survival (EFS) and overall survival (OS) was 78 ± 4.5% and 85 ± 3.9%, respectively. Relapsed patients had a 5-year OS of only 33 ± 14%. Multivariate analysis failed to demonstrate age, gender, lactate dehydrogenase level, presence of marrow and/or central nervous system disease to have independent prognostic value. These results suggest that this experimental approach is safe and results in similar outcomes as more prolonged childhood ALL regimens.

AB - Pediatric lymphoblastic lymphoma (LL) has utilized treatment strategies similar to childhood acute lymphoblastic leukaemia (ALL) with prolonged maintenance chemotherapy. We report the results of a pilot study to estimate the feasibility, toxicity and efficacy of a 12-month aggressive multi-agent chemotherapy regimen in children and adolescents with advanced LL. Between July 1994 and June 1997, 85 eligible children and adolescents with advanced LL (Stage III/IV) were enrolled on this pilot study. Patients achieving a complete response following induction and consolidation received six cycles of maintenance chemotherapy for a total duration of 12 months. Grade III/IV toxicities included: hematological (80%), infections (20%), stomatitis and elevated transaminases, (29%). There were a total of 19 events, 13 relapses, two secondary acute myeloid leukaemia and four toxic deaths (5%). The 5-year event-free survival (EFS) and overall survival (OS) was 78 ± 4.5% and 85 ± 3.9%, respectively. Relapsed patients had a 5-year OS of only 33 ± 14%. Multivariate analysis failed to demonstrate age, gender, lactate dehydrogenase level, presence of marrow and/or central nervous system disease to have independent prognostic value. These results suggest that this experimental approach is safe and results in similar outcomes as more prolonged childhood ALL regimens.

KW - Adolescents

KW - Children

KW - Intensified multiagent chemotherapy

KW - Lymphoblastic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=52649083671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649083671&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2008.07320.x

DO - 10.1111/j.1365-2141.2008.07320.x

M3 - Article

VL - 143

SP - 261

EP - 267

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -